From Individual Experts to Multidisciplinary Teams: How Shanghai Is Reshaping Cancer Care

Cancer treatment has become too complex for one specialist to manage alone. Surgery, systemic therapy, radiotherapy, pathology, molecular testing, imaging, genetics, nutrition, rehabilitation, and supportive care can all change the outcome. The challenge is not simply finding excellent doctors. It is making sure they work from the same information, toward the same goal, in the correct sequence.

This is the purpose of multidisciplinary care, commonly called MDT. In leading Shanghai cancer centers, MDT systems are helping move treatment away from fragmented appointments and toward coordinated decisions across the full patient journey.

Why One Cancer Expert Is No Longer Enough

A surgeon may determine whether a tumor can be removed. A medical oncologist may decide whether chemotherapy, targeted therapy, immunotherapy, or an antibody-drug conjugate should be given before or after surgery. A radiation oncologist may identify an organ-preserving option. A pathologist may discover that the original diagnosis or biomarker result needs revision. A radiologist may show that the disease is more or less extensive than first believed.

Each specialist can be correct within one discipline while the overall plan remains incomplete. Common risks of fragmented care include:

• Operating before necessary staging or preoperative treatment;
• Starting chemotherapy without complete pathology or molecular testing;
• Missing an organ-preserving radiotherapy option;
• Repeating scans, biopsies, or blood tests unnecessarily;
• Using incompatible treatment sequences;
• Delaying treatment while patients move between departments;
• Ignoring nutrition, rehabilitation, fertility, pain, or psychological needs;
• Failing to define who is responsible for follow-up.

MDT does not replace expert judgment. It connects expert judgments into one strategy.

What a Real MDT Consultation Is

A multidisciplinary tumor board brings relevant specialists together to review the same case. Depending on the cancer, participants may include:

• Surgical oncology or an organ-specific surgeon;
• Medical oncology or hematology;
• Radiation oncology;
• Diagnostic radiology and nuclear medicine;
• Pathology and molecular diagnostics;
• Gastroenterology, respiratory medicine, hepatology, or another organ specialty;
• Genetics, fertility, nutrition, rehabilitation, pain, and palliative care;
• Specialist nurses and case coordinators.

The discussion should answer specific questions: What is the diagnosis and stage? What is the treatment goal? Is surgery possible now or after treatment? Which biomarkers matter? What should happen first? What risks could interrupt the plan? When will the team reassess?

A true MDT produces a coordinated recommendation, not simply a list of opinions. It should identify the preferred plan, reasonable alternatives, unresolved questions, and the next responsible department.

Pathology and Imaging: The Foundation of Every MDT

No multidisciplinary discussion is stronger than the evidence placed in front of it. Pathology confirms the cancer type and can reveal grade, receptor status, molecular features, and treatment targets. Imaging defines location, extent, surgical anatomy, response, and recurrence.

Complex or unusual cancers may benefit from pathology review at a specialist center. The team may request original slides, tissue blocks, digital pathology, or repeat biomarker testing. Similarly, written imaging reports are not enough for many MDT decisions. Specialists often need the original CT, MRI, PET-CT, or ultrasound files in DICOM format.

Learn more about pathology and molecular diagnostics at Fudan University Shanghai Cancer Center.

Shanghai’s MDT Model

Shanghai’s major cancer institutions have different strengths, but their leading teams share a move toward disease-focused multidisciplinary care rather than isolated departmental treatment.

Fudan University Shanghai Cancer Center

As a specialist cancer hospital, Fudan University Shanghai Cancer Center integrates organ-specific surgery, medical oncology, radiation oncology, pathology, imaging, nuclear medicine, endoscopy, molecular diagnostics, clinical research, rehabilitation, and supportive care.

Disease centers for breast, lung, gastrointestinal, hepatobiliary and pancreatic, gynecologic, urologic, head and neck, bone and soft-tissue, and other cancers enable treatment to be discussed by teams familiar with the same tumor type. Explore the center’s six innovation teams shaping modern cancer care.

Zhongshan Hospital, Fudan University

Zhongshan Hospital combines high-level cancer care with major strengths in complex surgery, cardiovascular and organ-function management, interventional treatment, intensive care, imaging, and translational research.

Its MDT model is especially relevant when cancer treatment depends on liver reserve, vascular involvement, heart or lung function, interventional procedures, conversion treatment, or technically complex surgery. Read about Zhongshan Hospital’s innovation teams.

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Ruijin Hospital combines comprehensive medicine with strong programs in pancreatic surgery, gastric cancer, hematology, endocrinology, minimally invasive and robotic surgery, critical care, and emerging cellular and immune therapies.

This structure can be valuable for patients who need intensive perioperative assessment, complex medical management, or coordinated access to surgical and systemic-treatment innovation. Explore Ruijin Hospital’s cancer innovation teams.

MDT Is Most Valuable at Decision Points

Not every routine appointment requires a full tumor board. MDT review creates the greatest value when a decision can change the treatment pathway, including:

• A new diagnosis with multiple reasonable treatment options;
• Borderline resectable or locally advanced disease;
• A choice between surgery and organ preservation;
• Rare pathology or uncertain diagnosis;
• Conflicting imaging or biomarker results;
• A possible conversion from unresectable to resectable disease;
• Recurrence after surgery, radiotherapy, or multiple medicines;
• Re-irradiation or other high-risk local treatment;
• Oligometastatic disease where local treatment may matter;
• Clinical-trial consideration;
• A treatment plan limited by heart, lung, liver, kidney, or nutritional problems.

From Screening to Survivorship: The Full-Cycle Model

Multidisciplinary cancer care should not begin only after a late-stage diagnosis. A complete system connects the entire patient journey.

1. Risk Assessment and Screening

Family history, inherited risk, smoking, viral infection, chronic inflammation, age, and previous findings determine who needs screening and which test is appropriate. Gastroenterology, respiratory medicine, genetics, gynecology, and primary care may all contribute.

2. Diagnosis and Staging

Biopsy, pathology, molecular testing, high-quality imaging, endoscopy, and organ-function assessment should establish what the cancer is and how far it has spread before major treatment begins.

3. Treatment Sequencing

The MDT determines whether surgery, systemic therapy, radiotherapy, intervention, or another local treatment should come first. The sequence can be as important as the individual treatments.

4. Rehabilitation and Supportive Care

Nutrition, physical rehabilitation, pain management, fertility preservation, psychological support, stoma care, lymphedema prevention, swallowing therapy, and symptom control protect treatment tolerance and quality of life.

5. Surveillance and Long-Term Management

Follow-up should define who orders imaging, which biomarkers are useful, when endoscopy is needed, how late effects are monitored, and what symptoms should trigger urgent review.

Supportive and palliative care can begin alongside active anticancer treatment. It is not limited to the end of life. Learn more about palliative and supportive care at Fudan University Shanghai Cancer Center.

The Patient’s Role in a Successful MDT

Patients are not passive subjects of a tumor board. Their priorities can change the best plan. A treatment that offers the highest theoretical disease control may not be acceptable if it creates a level of functional loss that conflicts with the patient’s goals.

The team should understand:

• The patient’s main treatment goal;
• Current symptoms and daily function;
• Existing heart, lung, liver, kidney, or autoimmune conditions;
• Previous treatment side effects;
• Fertility, work, caregiving, communication, and travel needs;
• Preferences about surgery, stoma, organ preservation, or long-term medication;
• The patient’s tolerance for risk and uncertainty.

Shared decision-making does not mean asking the patient to choose without guidance. It means the team explains the evidence and trade-offs clearly enough for the patient to make an informed choice.

How to Recognize a Reliable Cancer Team

A strong team is not defined by a famous name alone. Patients should look for:

• Regular experience with the specific cancer and stage;
• Pathology and imaging review before major decisions;
• Access to surgery, medical oncology, and radiotherapy when relevant;
• A clear explanation of treatment goals and sequence;
• Willingness to discuss alternatives and uncertainty;
• Outcome and complication-management systems;
• Nutrition, rehabilitation, symptom, and survivorship support;
• Appropriate clinical-trial access without overselling experimental treatment;
• A written plan identifying the next step and responsible team.

Red flags include guaranteed cures, pressure to pay before records are reviewed, treatment chosen from one biomarker alone, refusal to discuss alternatives, or a plan that ignores pathology, stage, organ function, and previous therapy.

How to Prepare for an Efficient Shanghai Consultation

International patients can save time by preparing a structured case package before travel. It should include:

• A one-page timeline of symptoms, diagnosis, and treatment;
• Pathology reports plus slides, tissue blocks, or digital pathology when available;
• Original CT, MRI, PET-CT, ultrasound, endoscopy, or nuclear-medicine files;
• Operation notes and discharge summaries;
• Radiotherapy plans and dose records;
• Medication names, doses, dates, responses, and side effects;
• Molecular, genetic, and biomarker reports;
• Recent blood tests and organ-function results;
• A concise list of three to five priority questions.

Patients attending Fudan University Shanghai Cancer Center can also review the campus and appointment guide.

Questions an MDT Should Answer

• Is the diagnosis and stage fully confirmed?
• What is the treatment goal: cure, conversion, control, organ preservation, or symptom relief?
• What should happen first, and why?
• Which tests are still missing, and will they change management?
• What are the preferred plan and reasonable alternatives?
• What benefit and major risks are expected from each option?
• When will response be reassessed?
• What finding would cause the team to change direction?
• Who is responsible for nutrition, symptom control, rehabilitation, and follow-up?
• Is a clinical trial appropriate now or later?

How CMCS Supports Multidisciplinary Cancer Care in Shanghai

China Medical Concierge Shanghai (CMCS) is a health management and medical concierge company, not a hospital. We help international patients organize records, identify appropriate specialists in Shanghai, and coordinate communication across the patient journey.

Depending on the case, CMCS can assist with:

• Reviewing record completeness and organizing pathology, imaging, molecular results, and treatment history;
• Preparing a concise bilingual case summary and prioritized consultation questions;
• Identifying the department or combination of specialties most relevant to the decision;
• Coordinating appointments, travel preparation, on-site communication, and examination scheduling;
• Helping patients understand the sequence of consultations, testing, treatment, rehabilitation, and follow-up;
• Tracking action points from different departments so that recommendations do not become fragmented;
• Facilitating necessary communication with family members after receiving the patient’s authorization.

CMCS does not replace the treating physicians or make medical decisions. Remote record review or video consultation requires the physician’s approval and may not replace an in-person examination. Patients should provide authorization and complete, recent records before case coordination.

CMCS can usually address approximately three to five core questions during initial screening. If specific medical coordination is required, the service scope and applicable fee will be explained in advance.

Conclusion: Standardization, Collaboration, and Continuity

The future of cancer care does not belong to isolated experts working in parallel. It belongs to teams that confirm the diagnosis, compare treatment paths, sequence care intelligently, protect organ function, and remain responsible through rehabilitation and follow-up.

Shanghai’s leading centers show how surgery, medicine, radiotherapy, pathology, imaging, molecular diagnostics, and supportive care can function as one system. Standardized decisions, genuine collaboration, and full-cycle management are not administrative extras. They are part of effective cancer treatment.

Contact CMCS

For help organizing cancer records, identifying an appropriate multidisciplinary team in Shanghai, or planning a medical visit, contact us:

• Website: www.medicalsh.com
• Email: contract@medicalsh.com
• WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1

You may also submit your information through our contact page.

Medical notice: This article is for health education only and does not provide a diagnosis or individualized treatment recommendation. All tests, treatment sequences, procedures, medicines, and follow-up plans must be determined by qualified physicians using the patient’s complete medical information.